Last reviewed · How we verify
FPR Specialty Pharmacy — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Diclofenac Cream 8% | Diclofenac Cream 8% | phase 3 | Nonsteroidal anti-inflammatory drug (NSAID) | COX-1, COX-2 | Pain Management, Rheumatology |
Therapeutic area mix
- Pain Management, Rheumatology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Actavis Inc. · 1 shared drug class
- Amneal Pharmaceuticals, LLC · 1 shared drug class
- Amzell · 1 shared drug class
- Assaf-Harofeh Medical Center · 1 shared drug class
- Azienda USL Reggio Emilia - IRCCS · 1 shared drug class
- Bausch & Lomb Incorporated · 1 shared drug class
- Bayer · 1 shared drug class
- Abbott · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for FPR Specialty Pharmacy:
- FPR Specialty Pharmacy pipeline updates — RSS
- FPR Specialty Pharmacy pipeline updates — Atom
- FPR Specialty Pharmacy pipeline updates — JSON
Cite this brief
Drug Landscape (2026). FPR Specialty Pharmacy — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fpr-specialty-pharmacy. Accessed 2026-06-10.